Human IgG antibodies specific for Quercus agrifolia pollen epitopes (Anti-Q. agrifolia IgG)

Human IgG antibodies specific for Quercus agrifolia pollen epitopes are immunoglobulins produced by the human immune system in response to allergens from the Coast Live Oak (Quercus agrifolia), a significant source of seasonal allergens in the Western United States [Glovsky et al., 1991, J Allergy Clin Immunol]. These antibodies, particularly the IgG4 subclass, play a protective role in allergic individuals by acting as “blocking antibodies” [Shamji & Durham, 2017, J Allergy Clin Immunol]. They function by binding to specific epitopes on oak pollen proteins, such as the major allergen Que a 1, thereby preventing these allergens from cross-linking IgE antibodies on the surface of mast cells and basophils [Akdis & Akdis, 2014, J Allergy Clin Immunol]. This competition effectively inhibits the release of inflammatory mediators like histamine, which are responsible for the symptoms of allergic rhinitis and asthma. The induction of these specific IgG antibodies is a hallmark of successful allergen-specific immunotherapy (AIT) and serves as a key biomarker for the development of clinical tolerance [Durham & Penagos, 2016, J Allergy Clin Immunol]. Monitoring the levels of anti-Quercus agrifolia IgG helps clinicians evaluate the immunological shift from a Th2-driven allergic response to a more regulated immune state during desensitization therapy [Shamji et al., 2012, J Allergy Clin Immunol]. While these antibodies are not traditional drug targets, their production is the therapeutic goal of administering Quercus agrifolia pollen extracts.

Other names

Anti-Quercus agrifolia IgGCoast live oak-specific IgGOak pollen-specific IgGAnti-Que a IgG

Allergen immunotherapy (AIT) induces the production of allergen-specific IgG antibodies, particularly the IgG4 subclass, which act as “blocking antibodies” to compete with IgE for allergen binding, thereby preventing mast cell degranulation and the subsequent allergic cascade [Shamji & Durham, 2017, J Allergy Clin Immunol].